Détails de la réservation
- Le : 10 November 2017
- De : 11 h 00
- à : 12 h 30
- Salle : Salle de conférence
Détails de l'évènement
John Ebos
Assistant Professor of Oncology in the Departments of Cancer Genetics and Medicine at
Roswell Park Cancer Institute (RPCI),and is a member of the graduate faculty in the
Department of Pharmacology and Therapeutics at the State University of New York at
Buffalo.
“Modeling metastasis and drug resistance: Lessons from antiangiogenic therapy"
Résumé
One consistent (and often frustrating) aspect of cancer research is learning that a preclinical ‘breakthrough’ did not eventually lead to a new therapeutic benefit for patients. This may stem, at least in part, from the fact that new drugs are often tested in patients with advanced metastatic disease while mouse models typically examine only localized ‘primary’ tumors. This testing gap may explain why some inhibitors of the tumor microenvironment, including angiogenesis and immune-checkpoint inhibitors, often poorly predict why a drug may succeed (or fail) in clinical trials. My laboratory aims to study VEGF and PD-1 pathway inhibition in mouse models that recapitulate the steps of metastasis, including initial
primary tumor growth, surgery, and the generation of spontaneous distant disease. Our studies have
uncovered evidence that treatments can often have opposite effects, perhaps explaining why efficacy in
patients is often far more modest than predicted. This lecture will focus on recent results showing that offtarget
‘collateral’ effects of therapy can contribute to treatment failure and demonstrate the need for
continued collaboration to improve modeling approaches to better predict patient outcomes.
Invitation : Sébastien Benzekry – Monc Modeling in Oncology -Inria
Responsable
- Nom : Rocher Virginie